Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Selvita S.A. (SLV.WA)
Kraków, PL
Selvita S.A., a contract research organization (CRO), provides its services across Poland, throughout Europe, in the United States, and to global clients. The company is structured around two main divisions: its core Contract Research Organization (CRO) offerings and Bioinformatics. Within its drug discovery portfolio, Selvita delivers a comprehensive suite of services including assay development and screening, expertise in medicinal and synthetic chemistry, advanced computer-aided drug design leveraging artificial intelligence, structural biology, in vitro and in vivo pharmacology studies, ADME/DMPK assessments, and general analytical testing. Furthermore, Selvita extends its capabilities to pharmaceutical services, encompassing drug testing and bioanalytical analysis. These services cover development and optimization processes, validation and transfer, stability studies, rigorous quality control, and assistance with regulatory compliance. The organization also engages in diverse research and development activities, such as process research, bespoke laboratory-scale synthesis of New Chemical Entities (NCEs), industrial chemistry solutions, and the creation of isotopically labeled compounds. Support for the agrochemical industry is also part of their R&D offerings. Moreover, Selvita delivers specialized bio-data science and sophisticated software solutions tailored for data-centric organizations within the life science and healthcare sectors. Established in 2007, Selvita S.A. maintains its headquarters in Krakow, Poland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.18% | -0.83% | -14.43% | -30.51% | -37.60% | -32.24% | -4.92% | -59.53% | -60.54% | +40.61% | +40.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+6.6% Q1'26: -15.8% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+113.4% ★ Q1'26: -458.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+13.2% ★ Q1'26: +3.3% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+2.0% Q1'26: -9.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+1.6% Q1'26: -5.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×2.75× Q1'26: 6.82× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
137.36M
est: 140.87M (-2.5%)
|
310.92M
est: 305.00M (+1.9%)
|
360.68M
est: 415.02M (-13.1%)
|
346.72M
est: 329.02M (+5.4%)
|
342.01M
est: 342.95M (-0.3%)
|
364.47M
est: 368.40M (-1.1%)
|
389.44M
370.57M – 399.90M
+5.7% YoY
|
430.40M
401.81M – 462.65M
+10.5% YoY
|
479.90M
475.13M – 484.68M
+11.5% YoY
|
491.50M
463.01M – 517.19M
+2.4% YoY
|
532.80M
501.92M – 560.64M
+8.4% YoY
|
| EBITDA |
33.01M
est: 32.17M (+2.6%)
|
52.43M
est: 69.66M (-24.7%)
|
75.39M
est: 94.79M (-20.5%)
|
125.61M
est: 70.48M (+78.2%)
|
55.30M
est: 73.47M (-24.7%)
|
61.76M
est: 78.92M (-21.7%)
|
83.42M
79.38M – 85.67M
+5.7% YoY
|
92.20M
86.07M – 99.11M
+10.5% YoY
|
102.80M
101.78M – 103.83M
+11.5% YoY
|
105.29M
99.19M – 110.79M
+2.4% YoY
|
114.13M
107.52M – 120.10M
+8.4% YoY
|
| EBIT |
19.48M
est: 16.07M (+21.2%)
|
24.94M
est: 34.79M (-28.3%)
|
39.93M
est: 47.34M (-15.7%)
|
80.16M
est: 29.51M (+171.7%)
|
2.20M
est: 30.76M (-92.8%)
|
7.27M
est: 33.04M (-78.0%)
|
34.93M
33.23M – 35.87M
+5.7% YoY
|
38.60M
36.04M – 41.49M
+10.5% YoY
|
43.04M
42.61M – 43.47M
+11.5% YoY
|
44.08M
41.53M – 46.38M
+2.4% YoY
|
47.78M
45.02M – 50.28M
+8.4% YoY
|
| Net Income |
18.00M
est: 22.07M (-18.5%)
|
14.90M
est: 27.96M (-46.7%)
|
30.31M
est: 44.85M (-32.4%)
|
69.88M
est: 47.40M (+47.4%)
|
-6.10M
est: -9.63M (+36.7%)
|
813.0K
est: -182.84M (+100.4%)
|
15.98M
14.52M – 16.77M
+108.7% YoY
|
27.48M
22.14M – 41.64M
+72.0% YoY
|
40.80M
33.81M – 48.67M
+48.5% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
19.99M
est: 19.01M (+5.1%)
|
3.98M
est: 41.17M (-90.3%)
|
7.57M
est: 56.02M (-86.5%)
|
205.71M
est: 18.08M (+1,038.0%)
|
-33.42M
est: 18.84M (-277.4%)
|
-92.81M
est: 20.24M (-558.5%)
|
21.40M
20.36M – 21.97M
+5.7% YoY
|
23.65M
22.08M – 25.42M
+10.5% YoY
|
26.37M
26.10M – 26.63M
+11.5% YoY
|
27.00M
25.44M – 28.42M
+2.4% YoY
|
29.27M
27.58M – 30.80M
+8.4% YoY
|
| EPS |
1.05
est: 1.20 (-12.7%)
|
0.81
est: 1.52 (-46.8%)
|
1.42
est: 2.44 (-41.8%)
|
3.81
est: 2.58 (+47.5%)
|
-0.33
est: -0.53 (+37.3%)
|
0.04
est: -10.00 (+100.4%)
|
0.86
0.79 – 0.91
+108.6% YoY
|
1.59
1.21 – 2.27
+85.4% YoY
|
2.25
1.84 – 2.65
+41.7% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 58.2K | 0.65% |
| 2 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 3.0K | 0.07% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 9.2K | 0.39% |
| 4 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 260.66 | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adrijana Vinter | Global Head of Drug Discovery & Member of the Management Board | 1M | — |
| Boguslaw Stanislaw Sieczkowski | Chairman of Management Board & Chief Executive Officer | 803.0K | male |
| Milosz Kazimierz Gruca | Global Head of Drug Development, Executive Vice President & Vice President of Management Board | 753.0K | — |
| Paul D. Overton | Chief Commercial Officer & Management Board Member | 667.0K | — |
| Dariusz Tomasz Kurdas | Chief Financial Officer & Member of the Management Board | 490.0K | male |
| Tomasz Narojczyk | Executive Officer | 376.0K | male |
| Anna Leja | Executive Officer | 376.0K | — |
| Marija Gradecak Galovic | Executive Officer | 376.0K | — |
| Natalia Walas Marcinek | Executive Officer | 376.0K | — |
| Dawid Patryk Radziszewski | General Counsel & Member of the Management Board | 191.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SLV.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
